Exploring Vaccine Manufacturing And Quality Oversight In The Covid-19 Era And Beyond
- How do you maintain vaccine manufacturing, oversight and working with 3rd party manufacturers during the current pandemic?
- Considerations for QA and QC in Emergent’s vaccine manufacturing
- What are the consequences of working in a resource limited virtual setting for quality control, analytical development, quality assurance and regulatory affairs?
- Technical, quality, business and implementation factors for manufacturing vaccines – both Emergent’s internal oversight and oversight of work performed by CDMO’s on Emergent’s behalf
- How does the COVID-19 pandemic shape the future of our Quality Unit model